References

1. Tempero MA. Incremental successes lead to improved patient care. http://gicasym.asco.org/incremental-successes-lead-improved-patient-care. Accessed January 23, 2013.


Continue Reading

2. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed January 23, 2013.

3. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). http://gicasym.asco.org/content/106143-133. Accessed January 23, 2013.

4. www.clinicaltrials.gov. NCT00844649. Phase III study of ABI-007 (albumin-bound paclitaxel) plus gemcitabine versus gemcitabine in metastatic adenocarcinoma of the pancreas. http://clinicaltrials.gov/show/NCT00844649. Accessed January 23, 2013.

5. “Nab-Paclitaxel Plus Gemcitabine New Standard of Care for First-Line Metastatic Pancreatic Cancer.”  http://gicasym.asco.org/nab-paclitaxel-plus-gemcitabine-new-standard-care-first-line-metastatic-pancreatic-cancer. Accessed January 23, 2013.

6. Aufforth RD, Baker JJ, Witek MA, et al. Circulating tumor cells as a possible marker for micrometastatic disease in patients with localized pancreatic cancer.  http://gicasym.asco.org/content/105456-133. Accessed January 24, 2013.

7. Zubritsky L, Alkhateeb A, Leitzel K, et al. Pretreatment serum ferritin and overall survival in metastatic pancreatic cancer. http://gicasym.asco.org/content/104829-133. Accessed January 28, 2013.

8. Sangar V, Ricigliano M, O’Reilly EM, et al. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. http://gicasym.asco.org/content/106051-133. Accessed January 24, 2013.

9. Tzung-Kai Chen K, Singla S, Papavasiliou P, Arrangoiz R, Gaughan JP, Hoffman JP. Patterns of recurrence and outcomes in pancreatic cancer. http://gicasym.asco.org/content/105288-133. Accessed January 25, 2013.

10. Deplanque G, Demarchi M, Hebbar M, et al. Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. http://gicasym.asco.org/content/105737-133. Accessed January 28, 2013.

11. www.clinicaltrials.gov. NCT00789633. A phase 3 study to compare efficacy and safety of masitinib in combination with gemcitabine, to placebo in combination with gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer. http://clinicaltrials.gov/ct2/show/NCT00789633. Accessed January 28, 2013.

12. Infante JR, Somer, BG, Park, JO, et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. http://gicasym.asco.org/content/105967-133. Accessed January 28, 2013.

13. www.clinicaltrials.gov. NCT01231581. Study of GSK1120212 plus gemcitabine vs placebo plus gemcitabine in metastatic pancreatic cancer. http://clinicaltrials.gov/show/NCT01231581. Accessed January 28, 2013.